Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is pleased to announce the receipt of a Japan Patent Office allowance for Patent Family 4, extending to 2041, covering RECCE® 327 (R327) and RECCE® 529 (R529). This patent acknowledges the processes for preparation and extensive applications of these anti-infectives in treating bacterial and viral infections. With Japan being a significant pharmaceutical market and the antibiotic resistance market expected to grow, this recognition reinforces our commitment to innovative therapies. Our CEO, James Graham, cites this as a strong endorsement of our New Class of Anti-Infectives and our global impact.

The approval from the Japan Patent Office aligns with our ongoing efforts in other key markets such as Australia, Canada, and Israel, with additional submissions in the Patent Cooperation Treaty pipeline. By addressing critical unmet medical needs and staying dedicated to global patent protection, we aim to provide meaningful solutions to patients worldwide. 

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is pleased to announce the receipt of a Japan Patent Office allowance for Patent Family 4, extending to 2041, covering RECCE® 327 (R327) and RECCE® 529 (R529). This patent acknowledges the processes for preparation and extensive applications of these anti-infectives in treating bacterial and viral infections. With Japan being a significant pharmaceutical market and the antibiotic resistance market expected to grow, this recognition reinforces our commitment to innovative therapies. Our CEO, James Graham, cites this as a strong endorsement of our New Class of Anti-Infectives and our global impact.<br/><br/>The approval from the Japan Patent Office aligns with our ongoing efforts in other key markets such as Australia, Canada, and Israel, with additional submissions in the Patent Cooperation Treaty pipeline. By addressing critical unmet medical needs and staying dedicated to global patent protection, we aim to provide meaningful solutions to patients worldwide. We invite investors to engage with us and learn more about our advancements and potential impact on the healthcare landscape.

Japan Patent Allowance for RECCE Anti-Infectives

Summary